Nebivolol Cinfa (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Cinfa, is a beta blocker presented as an oral tablet for oral use. It is used to treat hypertension in adult patients and works by selectively blocking β1‑adrenergic receptors while promoting nitric‑oxide mediated vasodilation.

GNH USA supplies Nebivolol Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic blocker indicated for conditions within the hypertension disease family.

Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. Essential hypertension: provides sustained blood pressure control in adults. Isolated systolic hypertension: reduces elevated systolic pressure in elderly patients.

Nebivolol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness: especially after the first dose. - Fatigue: general feeling of tiredness. - Nasal congestion: mild blockage of nasal passages. - Gastrointestinal discomfort: nausea or mild abdominal pain.

Serious or Rare Side Effects: - Bradycardia: heart rate markedly below normal. - Severe hypotension: dangerous drop in blood pressure. - Heart block: impaired electrical conduction. - Acute bronchospasm: sudden narrowing of airways. - Allergic reactions: rash, itching, or swelling.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Cardiovascular assessment: evaluate baseline heart rate and blood pressure. - Concomitant β‑blockers: avoid duplicate therapy to prevent excessive bradycardia. - Renal or hepatic impairment: adjust monitoring frequency as needed. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Nebivolol can interact with several drug classes; awareness helps prevent clinically significant events.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma levels. - Other β‑blockers: additive negative chronotropic effects. - Calcium channel blockers (verapamil, diltiazem): can enhance bradycardia.

Moderate Interactions (Monitor Closely): - Antihypertensives (ACE inhibitors, ARBs): may cause excessive blood pressure reduction. - Diuretics: risk of orthostatic hypotension. - Antidiabetic agents: possible masking of hypoglycemia symptoms.